The Role of Cytokines and Molecular Pathways in Lung Fibrosis following SARS-CoV-2 Infection: A Physiopathologic (Re)view

Mihai Lazar,Mihai Sandulescu,Ecaterina Constanta Barbu,Cristina Emilia Chitu-Tisu,Darie Ioan Andreescu,Andreea Nicoleta Anton,Teodora Maria Erculescu,Alexandru Mihai Petre,George Theodor Duca,Vladimir Simion,Isabela Felicia Padiu,Cosmina Georgiana Pacurar,Ruxandra Rosca,Teodor Mihai Simian,Constantin Adrian Oprea,Daniela Adriana Ion

DOI: https://doi.org/10.3390/biomedicines12030639

IF: 4.757

2024-03-14

Biomedicines

Abstract:SARS-CoV-2 infection is a significant health concern that needs to be addressed not only during the initial phase of infection but also after hospitalization. This is the consequence of the various pathologies associated with long COVID-19, which are still being studied and researched. Lung fibrosis is an important complication after COVID-19, found in up to 71% of patients after discharge. Our research is based on scientific articles indexed in PubMed; in the selection process, we used the following keywords: "lung fibrosis", "fibrosis mediators", "fibrosis predictors", "COVID-19", "SARS-CoV-2 infection", and "long COVID-19". In this narrative review, we aimed to discuss the current understanding of the mechanisms of initiation and progression of post-COVID-19 lung fibrosis (PC-19-LF) and the risk factors for its occurrence. The pathogenesis of pulmonary fibrosis involves various mediators such as TGF-β, legumain, osteopontin, IL-4, IL-6, IL-13, IL-17, TNF-α, Gal-1, Gal-3, PDGF, and FGFR-1. The key cellular effectors involved in COVID-19 lung fibrosis are macrophages, epithelial alveolar cells, neutrophils, and fibroblasts. The main fibrosis pathways in SARS-CoV-2 infection include hypoxemia-induced fibrosis, macrophage-induced fibrosis, and viral-fibroblast interaction-induced fibrosis.

biochemistry & molecular biology,medicine, research & experimental,pharmacology & pharmacy

What problem does this paper attempt to address?

The paper attempts to address the following problem: exploring the mechanisms and risk factors of lung fibrosis after SARS-CoV-2 infection.

Specifically, the paper focuses on the following points:

1. **Mechanism Research**:
- Discuss the initiation and progression mechanisms of post-COVID-19 lung fibrosis (PC-19-LF) after SARS-CoV-2 infection.
- Analyze the roles of cytokines, growth factors, and enzymes related to lung fibrosis.
- Describe the roles of key cellular effectors such as macrophages, alveolar epithelial cells, neutrophils, and fibroblasts in lung fibrosis.
- Elucidate the main pathways of lung fibrosis, including hypoxia-induced fibrosis, macrophage-induced fibrosis, and virus-fibroblast interaction-induced fibrosis.

2. **Risk Factors**:
- Identify prognostic markers and risk factors associated with the occurrence of PC-19-LF.
- Explore the high prevalence of PC-19-LF in different patient groups, such as males and patients with chronic obstructive pulmonary disease (COPD).

3. **Pathophysiology**:
- Provide a detailed description of various mediators involved in lung fibrosis, including TGF-β, legumain, osteopontin, IL-4, IL-6, IL-13, IL-17, TNF-α, Gal-1, Gal-3, PDGF, and FGFR-1.
- Explain how these mediators promote the development of lung fibrosis through different signaling pathways, such as TGF-β/Smad, JAK/STAT6, STAT3, etc.

4. **Clinical Significance**:
- Emphasize the importance of understanding these mechanisms and risk factors for the prevention and treatment of lung fibrosis after SARS-CoV-2 infection.

In summary, this paper aims to comprehensively understand the pathophysiological mechanisms of lung fibrosis after SARS-CoV-2 infection by reviewing existing scientific literature and to provide a theoretical basis for future clinical research and treatment.